Head-to-head evidence
BCD-264 vs Daratumumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: CD38 · full Multiple Myeloma pipeline
BCD-264
Marketed by Biocad
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Daratumumab
Marketed by Johnson & Johnson
NCT02076009 · Phase 3 · completed
This was a large randomized, open-label trial with an active comparator, enrolling 286 participants in the daratumumab group and 283 in the control group. Progression-free survival was the hard clinical primary endpoint, but the registry does not report a complete treatment comparison or statistical significance for it, so the result cannot be clearly classified as met.
Next expected readout: October 2026 · NCT06140966 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BCD-264's landscape · Daratumumab's landscape